First Published Resveratrol Human Clinical Trial for Glucose Management

Albert Einstein Medical College reported Tuesday that the pilot study undertaken using Biotivia Transmax resveratrol at doses of 1, 1.5 and 2 grams (2, 3 and 4 capsules) daily over a period of 4 weeks resulted in two important positive findings for pre diabetes and diabetes sufferers. First, insulin sensitivity was increased. The potential benefit of this finding is that patients with diabetes may be able to manage their condition with either no insulin or fewer insulin injections if they also take a daily dose of resveratrol. In many cases this could mean that diet and exercise alone could be sufficient to maintain healthy blood sugar levels. The second finding in this study was that the spikes of blood sugar which diabetics experience after consuming a meal containing sugar or other carbohydrates was greatly reduced. This is an important potential benefit for diabetics and pre diabetics because it prevent the damage such spikes cause to various organs and cells in the body. Taken together these results point to a potentially safe and effective new way for the millions of diabetes patients and those who are glucose intolerate to significantly improve their quality of life. Dr Crandall, the study coordinator at the Albert Einstein Medical College, stated, “We were able to detect differences within the narrow dose range studied.”

The landmark study, which is the first of its type to be published in a major peer reviewed scientific journal, the Journal of Gerontology, validated resveratrol's potential value as a preventative and treatment for diabetics and persons with a condition called pre diabetes that, over time, evolves into full fledged diabetes.

The group of 10 subjects which were given either 2 or 4 transmax resveratrol capsules daily were all suffering from glucose intolerance, often an early indicator of impending Type 2 Diabetes. All ten subjects experienced significant improvement in their ability to tolerate glucose.

A further benefit of the Transmax over some of the more recent diabetes pharmaceutical treatments is the no side effects were detected and nor were any changes in body weight, blood lipids or blood pressure observed.

Dr. Crandall stated, “Together these results suggest that resveratrol shows promise as a new therapeutic strategy for and important and highly prevalent age-related metabolic disorder.

The study was funded by the National Institutes on Aging, the National Institutes of Health, and the Einstein Diabetes Research and Training Center. The resveratrol used in the study was a supplement named Transmax, manufactured by Biotivia LLC of New York.

Download the study overview.